Purpose: The purpose of this study was to evaluate the short- and long-term efficacy and toxicity of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody h-R3 when combined with radiotherapy for the treatment of locally advanced nasopharyngeal carcinoma (NPC).
Methods: 35 patients with stage III-IVb NPC with moderate- or strong-intensity EGFR expression were randomly divided into either a radiotherapy alone group or a group receiving radiotherapy combined with h-R3.
Results: The complete remission (CR) rates of the combination group at three time points were significantly higher (p<0.05) than those of the radiotherapy alone group. Overall survival, 3-year local control rate, and no distant metastasis rate did not differ between the two groups. No severe toxicity was noticed.
Conclusion: h-R3 is an agent with good safety profile which could help enhance the radiation antitumor effect in locally advanced NPC, but it did not seem to exhibit significant long-term efficacy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Bimetallic Aluminum 5,6-Dihydro-7,7-dimethyl quinolin-8-olates as Pro-Initiators for the ROP of ε-CL; Probing the Nuclearity of the Active Initiator.
Polymers (Basel)
July 2018
Key Laboratory of Engineering Plastics and Beijing National Laboratory for Molecular Science, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
Six examples of aluminum 5,6-dihydro-7,7-dimethylquinolin-8-olates, [{2-R¹-7,7-Me₂-8-R²C₉H₆N-8-O}AlR³₂]₂ (R¹ = R² = H, R³ = Me ; R¹ = R² = H, R³ = Et ; R¹ = R² = H, R³ = -Bu ; R¹ = Cl, R² = H, R³ = Me ; R¹ = H, R² = R³ = Me ; R¹ = Cl, R² = R³ = Me ), have been prepared by treating the corresponding pro-ligand (⁻) with either AlMe₃, AlEt₃ or Al(-Bu)₃. All complexes have been characterized by ¹H and C NMR spectroscopy and in the case of and by single crystal X-ray diffraction; dimeric species are a feature of their molecular structures. In the presence of PhCH₂OH (BnOH), ⁻ displayed good control and efficiency for the ROP of ε-CL with almost 100% conversion achievable in 10 min at 90 °C; the chloro-substituted and notably exhibited the lowest activity of the series.
View Article and Find Full Text PDFTreatment Outcomes of 257 Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Nimotuzumab Plus Intensity-Modulated Radiotherapy with or without Chemotherapy: A Single-Institution Experience.
Transl Oncol
February 2018
Department of Digital Earth, Institute of Remote Sensing and Digital Earth, CAS, Beijing, 100101, People's Republic of, China. Electronic address:
Objectives: To report the long-term outcome and toxicity of locoregionally advanced nasopharyngeal carcinoma (LA NPC) treated with nimotuzumab (h-R3) plus intensity-modulated radiotherapy (IMRT) with or without chemotherapy.
Methods: From May 2008 to March 2014, 3022 newly histology-proven, nonmetastatic NPC patients were retrospectively reviewed; among them, 257 patients treated with h-R3 were enrolled in this study. The patients' age range was between 10 and 76 years.
Nimotuzumab treatment and outcome analysis in patients with leptomeningeal metastasis from nonsmall cell lung cancer.
J Cancer Res Ther
December 2016
Department of Oncology, Chinese PLA General Hospital, Beijing, China.
Objective: Leptomeningeal metastasis (LM) leades a devastating consequence in patients with nonsmall cell lung cancer(NSCLC). Treatment is very limited for patients with LM. We introduced to use nimotuzumab (also known as h-R3) combined with methotrexate for treating LM in NSCLC patients.
View Article and Find Full Text PDFReversal of multidrug resistance in breast cancer MCF-7/ADR cells by h-R3-siMDR1-PAMAM complexes.
Int J Pharm
September 2016
School of Medicine, Tsinghua University, Beijing 100084, China; Collaborative Innovation Center for Biotherapy, Tsinghua University, Beijing 100084, China. Electronic address:
Multidrug resistance (MDR) among breast cancer cells is the paramount obstacle for the successful chemotherapy. In this study, anti-EGFR antibody h-R3 was designed to self-assembled h-R3-siRNA-PAMAM-complexes (HSPCs) via electrostatic interactions for siRNA delivery. The physicochemical characterization, cell uptake, MDR1 silencing efficiency, cell migration, cell growth and cell apoptosis were investigated.
View Article and Find Full Text PDFA phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer.
Chin J Cancer Res
February 2016
Departments of Thoracic Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, China.
Background: To determine the safety and therapeutic efficacy of nimotuzumab (h-R3) combined with docetaxel in advanced non-small-cell lung cancer (NSCLC) patients who have failed to respond to prior first-line chemotherapy.
Methods: In this single-center, open-label, dose-escalating phase I trial, patients with epidermal growth factor receptor (EGFR)-expressing stage IV NSCLC were treated with nimotuzumab plus docetaxel according to a dose escalation schedule. The safety and efficacy of the combination treatment were observed and analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!